Overview

A Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis (Measure Up 2)

Status:
Active, not recruiting

Trial end date:
2025-12-03

Target enrollment:

Participant gender:

Summary

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe AD who are candidates for systemic therapy.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Upadacitinib